Genocea Biosciences (NASDAQ:GNCA) Cut to Strong Sell at Zacks Investment Research


Share on StockTwits

Zacks Investment Research downgraded shares of Genocea Biosciences (NASDAQ:GNCA) from a hold rating to a strong sell rating in a research report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research firms have also recently commented on GNCA. Needham & Company LLC cut their target price on shares of Genocea Biosciences from $7.00 to $6.00 and set a buy rating for the company in a research note on Thursday, February 11th. SVB Leerink upped their price objective on shares of Genocea Biosciences from $5.00 to $6.00 and gave the company an outperform rating in a research note on Tuesday.

Shares of Genocea Biosciences stock opened at $2.30 on Tuesday. The firm has a 50-day simple moving average of $2.82 and a two-hundred day simple moving average of $2.60. The company has a market cap of $123.09 million, a P/E ratio of -1.59 and a beta of 2.33. Genocea Biosciences has a fifty-two week low of $1.68 and a fifty-two week high of $5.75.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Wednesday, February 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). As a group, sell-side analysts expect that Genocea Biosciences will post -0.96 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Genocea Biosciences in the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC lifted its holdings in Genocea Biosciences by 87.8% during the 4th quarter. Renaissance Technologies LLC now owns 395,763 shares of the biotechnology company’s stock worth $958,000 after buying an additional 185,069 shares in the last quarter. Personal Capital Advisors Corp acquired a new stake in Genocea Biosciences during the 4th quarter worth approximately $36,000. Finally, GSA Capital Partners LLP acquired a new stake in Genocea Biosciences during the 4th quarter worth approximately $316,000. Hedge funds and other institutional investors own 53.78% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Featured Article: Dividend Kings

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.